Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian...
PR Newswire
More News
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SAN JOSE, Calif., Aug. 18, 2026 Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose...
PR Newswire
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Zacks
New Strong Buy Stocks for July 22nd
HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
Zacks
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics (NASDAQ:BRNS)read more...
Benzinga
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology PR Newswire SAN JOSE, Calif., July 14, 2026 Notice of...
PR Newswire
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date PR Newswire SAN JOSE, Calif., July 6, 2026 Multiple Patients...
PR Newswire
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 PR Newswire SAN JOSE, Calif., June 29, 2026 Composition of...
PR Newswire
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium Anixa Biosciences Reports Positive Data from Completed Breast...
PR Newswire

Advertisement|Remove ads.